Etoricoxib Induced Skin Rashes: Case Report
1, 2, 2, 2, 1
- 1BLDEA’s College of Pharmacy, Department of Pharmacy Practice Vijaypura, Karnataka, INDIA.
- 2Intern, Pharm D, BLDEA’s College of Pharmacy, Vijaypura, Karnataka, INDIA.
CORRESPONDENCE
Syed Zia Inamdar
BLDEA’s College of Pharmacy, Department of Pharmacy Practice Vijaypura, Karnataka, INDIA.
Volume 10, Issue 3 · pp. 227-229 · 2017 · DOI: 10.5530/ijopp.10.3.46
ABSTRACT
Etoricoxib comes under the class Non-steroidal anti-inflammatory drugs (NSAIDS). It is a selective Cyclooxygenenase-2 enzyme inhibitor which is used mainly for its analgesic effects. Although it is highly efficacious in pain management, the safety profile of COX-2 inhibitor is yet not established in a broader sense. A patient admitted to the medicine ward of a tertiary care hospital with complaints of skin rashes over the face, trunk and extremities. The detailed history of present illness and past medical /medication history revealed the use of Etoricoxib by the patient for the past one month to treat his Rheumatoid Arthritis. it was suspected that the allergic reaction was caused due to the use of Etoricoxib. The suspected drug Etoricoxib was immediately stopped and the patient was managed symptomatically. The Naranjo scale was used to assess the causality of reaction and a score of 7 was obtained, indicating there was a “probable” causal relationship between the suspected drug and the reaction. Severity of the reaction was assessed using Hartwig’s severity assessment scale and found out to be a “moderately” severe adverse reaction.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Inamdar, S. Z., Joseph, R. P., Pradeepti, K., Ashwini, N., & Kulkarni, R. V. (2017). Etoricoxib Induced Skin Rashes: Case Report. Indian Journal of Pharmacy Practice, 10(3), 227-229. https://doi.org/10.5530/ijopp.10.3.46
Copyright and licence
© 2017 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0